ENDRA Life Sciences (NASDAQ:NDRA) Given New $25.00 Price Target at Ascendiant Capital Markets

ENDRA Life Sciences (NASDAQ:NDRA) had its target price decreased by Ascendiant Capital Markets from $27.00 to $25.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Ascendiant Capital Markets’ price objective would indicate a potential upside of 354.55% from the stock’s current price.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of ENDRA Life Sciences in a research note on Monday, April 20th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, ENDRA Life Sciences has a consensus rating of “Hold” and an average price target of $25.00.

ENDRA Life Sciences Price Performance

ENDRA Life Sciences stock opened at $5.50 on Monday. The firm has a 50-day moving average of $4.99 and a 200-day moving average of $4.75. ENDRA Life Sciences has a one year low of $2.96 and a one year high of $11.96. The company has a market cap of $6.99 million, a price-to-earnings ratio of -0.67 and a beta of -0.04.

ENDRA Life Sciences (NASDAQ:NDRA) last posted its quarterly earnings data on Friday, May 15th. The company reported ($1.09) EPS for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.14. As a group, sell-side analysts expect that ENDRA Life Sciences will post -4.65 earnings per share for the current year.

Institutional Investors Weigh In On ENDRA Life Sciences

An institutional investor recently bought a new position in ENDRA Life Sciences stock. Altium Capital Management LLC bought a new stake in ENDRA Life Sciences Inc. (NASDAQ:NDRA) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences accounts for about 0.9% of Altium Capital Management LLC’s investment portfolio, making the stock its 17th biggest holding. Altium Capital Management LLC owned approximately 6.92% of ENDRA Life Sciences as of its most recent SEC filing. 1.19% of the stock is currently owned by institutional investors and hedge funds.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.